Stay updated on Vemurafenib & Cobimetinib in BRAF V600E Craniopharyngioma Clinical Trial
Sign up to get notified when there's something new on the Vemurafenib & Cobimetinib in BRAF V600E Craniopharyngioma Clinical Trial page.

Latest updates to the Vemurafenib & Cobimetinib in BRAF V600E Craniopharyngioma Clinical Trial page
- CheckyesterdayChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1, indicating a new release. The Back to Top link has been removed.SummaryDifference0.1%
- Check9 days agoChange DetectedThe web page has undergone significant updates, including the addition of specific facility names and locations, as well as a new reference to a medical study on BRAF-MEK inhibition in craniopharyngiomas. Additionally, several previous location and disease-related terms have been removed.SummaryDifference4%
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check44 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.8%
- Check51 days agoChange DetectedThe web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.SummaryDifference0.1%
Stay in the know with updates to Vemurafenib & Cobimetinib in BRAF V600E Craniopharyngioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Vemurafenib & Cobimetinib in BRAF V600E Craniopharyngioma Clinical Trial page.